Article
Genomic profiling for clinical decision making in myeloid neoplasms and acute leukemia.
Blood - 24 Nov 2022
Duncavage Eric J, Bagg Adam, Hasserjian Robert P, DiNardo Courtney D, Godley Lucy A, Iacobucci Ilaria, Jaiswal Siddhartha, Malcovati Luca, Vannucchi Alessandro M, Patel Keyur P, Arber Daniel A, Arcila Maria E, Bejar Rafael, Berliner Nancy, Borowitz Michael J, Branford Susan, Brown Anna L, Cargo Catherine A, Döhner Hartmut, Falini Brunangelo, Garcia-Manero Guillermo, Haferlach Torsten, Hellström-Lindberg Eva, Kim Annette S, Klco Jeffery M, Komrokji Rami, Lee-Cheun Loh Mignon, Loghavi Sanam, Mullighan Charles G, Ogawa Seishi, Orazi Attilio, Papaemmanuil Elli, Reiter Andreas, Ross David M, Savona Michael, Shimamura Akiko, Skoda Radek C, Solé Francesc, Stone Richard M, Tefferi Ayalew, Walter Matthew J, Wu David, Ebert Benjamin L, Cazzola Mario
Abstract excerpt
Myeloid neoplasms and acute leukemias derive from the clonal expansion of hematopoietic cells driven by somatic gene mutations. Although assessment of morphology plays a crucial role in the diagnostic evaluation of patients with these malignancies, genomic characterization has become increasingly important for accurate diagnosis, risk assessment, and therapeutic decision making. Conventional cytogenetics, a...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.